Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04463615 · ClinicalTrials.gov registry record · Phase 2
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04463615: Completed Phase 2 study, sponsored by City of Hope Medical Center.
NCT04463615 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04463615, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Defined as the proportion of patients with a documented response (complete response \[CR\] or partial \[PR\]) any time during study treatment. Response will be categorized by modified severity weighted assessment tool (mSWAT). Will be calculated along with the Clopper Pearson binomial 95% exact confidence intervals. The treatment response was assessed after each 28-day cycle treatment.
Interventions
- DRUG Leflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 2 |
What the finished NCT04463615 record still lists
NCT04463615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Leflunomide is the first listed.
NCT04463615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04463615 about?
NCT04463615 is a clinical study titled "Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders". This trial studies how well leflunomide works for the treatment of patients with CD30+ lymphoproliferative disorders that have come back (relapsed) or do not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT04463615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-05-05. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT04463615?
The interventions under investigation include: Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04463615?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04463615's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI